In a CNBC International interview, IHH Healthcare CEO Dr. Prem Kumar Nair highlighted how IHH is elevating patient care by investing in high-end diagnostic capabilities through IHH Laboratories—a strategic move to position the group as a regional and global leader in laboratory medicine.

Dr. Prem emphasized that diagnostic services, including those provided by Parkway Laboratories, are shifting towards advanced technologies such as genetic testing, precision medicine, and genomics. These specialized, high-value tests have traditionally required samples to be sent overseas to institutions like the Mayo Clinic. Now, IHH aims to build regional reference laboratories—starting from Singapore—to localize these advanced testing capabilities. This not only enhances turnaround times but also reinforces IHH’s commitment to delivering world-class diagnostic services closer to home.